N,4cis-Dimethyl-cyclohexylamin | 2523-87-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,4cis-Dimethyl-cyclohexylamin
• CAS: 2523-87-7
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: YBPHGVBAJQGYDH-OCAPTIKFSA-N

物化性质

• 沸点：
  196.0±0.0 °C(Predicted)
• 密度：
  0.84±0.1 g/cm3(Predicted)

文献信息

• OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：Braun Alain

  公开号：US20070149562A1

  公开（公告）日：2007-06-28

  The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

  本发明涉及根据本文所定义的式（I）的化合物，这些化合物是黑色素皮质素受体激动剂，涉及其制备以及在治疗或预防肥胖、糖尿病和可能影响两性的性功能障碍中的治疗用途，治疗心血管疾病，以及抗炎症用途或治疗酒精依赖症。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Pharmacyclics, Inc.

  公开号：US20140039186A1

  公开（公告）日：2014-02-06

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文揭示了一些与布鲁顿酪氨酸激酶（Btk）形成共价键的化合物。还描述了Btk的不可逆抑制剂。本文披露了制备这些化合物的方法。还披露了包括这些化合物的制药组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合使用，用于治疗自身免疫疾病或状况、异体免疫疾病或状况、癌症（包括淋巴瘤）和炎症性疾病或状况。
• DEAZAPURINES AND USES THEREOF
  申请人：Daun Jane

  公开号：US20110105427A1

  公开（公告）日：2011-05-05

  The present invention provides compounds having formula (I): wherein R 1 , R 2 , R 3 and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally.

  本发明提供具有以下式子（I）的化合物：其中R1，R2，R3和n如本文中通常和在类和子类中所述，并且此外提供其药物组成物和使用它们治疗炎症或自身免疫和增殖性疾病以及作为细胞黏附分子表达和炎症细胞因子信号转导的抑制剂的方法。
• INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS
  申请人：Pharmacyclics, Inc.

  公开号：US20140079690A1

  公开（公告）日：2014-03-20

  Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

  本文描述了不可逆的Btk抑制剂化合物，以及使用这种不可逆抑制剂治疗由实体瘤存在或发展所特征的疾病和障碍的方法。
• METHODS OF TREATING FIBROSIS
  申请人：Pharmacyclics LLC

  公开号：US20160199376A1

  公开（公告）日：2016-07-14

  Disclosed are methods of treating fibrosis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of an ACK inhibitor (e.g., a BTK inhibitor, such as for example an irreversible BTK inhibitor, such as for example, ibrutinib).

  本发明涉及一种治疗患者纤维化的方法，包括向需要治疗的患者施用治疗有效量的ACK抑制剂（例如，BTK抑制剂，例如不可逆的BTK抑制剂，例如ibrutinib）。